[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bay National Corp (BAYN)

Bay National Corp (BAYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 0
  • Shares Outstanding, K 0
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/01/70
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Finance
  • INDUSTRY GROUPING Banks - Southeast

Most Recent Stories

More News
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA ® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

If approved for this investigational new use, KERENDIA ® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2 -mutated...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

Up to 90% of menstruators experience PMS symptoms 1 , many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol ® ...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

Campaign launches with a Walmart community event and food drive in Clovis, CA on May 14 Additional food collection will take place at Luke Bryan Farm Tour stops in Clovis (May 15) and...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

KEY FACTS The Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

Perfuse Therapeutics’ investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR) High...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing

The Latest Breakthrough Study from Leaps by Bayer and BCG reveals why optimism varies by technology, region, and context, with varying trends in China, Germany, and the US Younger generations...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)

Business Summary

Bay National Corporation is a bank holding company for Bay National Bank. The Bank accepts checking and savings deposits and offers a wide range of commercial and industrial, real estate, consumer and residential mortgage loans. The Bank's primary market areas are the Baltimore Metropolitan area, Baltimore-Washington...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 0.0100
1st Support Level N/A
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.0100
Fibonacci 61.8% 0.0100
Fibonacci 50% 0.0100
Fibonacci 38.2% 0.0100
Last Price 0.0100
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.